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Abstract
Background: Terbium has attracted the attention of researchers and physicians due to the existence of four medically
interesting radionuclides, potentially useful for SPECT and PET imaging, as well as for α- and β−-radionuclide therapy. The
aim of this study was to produce 152Tb (T1/2 = 17.5 h, Eβ+av = 1140 keV) and evaluate it in a preclinical setting in order to
demonstrate its potential for PET imaging. For this purpose, DOTANOC was used for targeting the somatostatin receptor
in AR42J tumor-bearing mice.
Methods: 152Tb was produced by proton-induced spallation of tantalum targets, followed by an online isotope
separation process at ISOLDE/CERN. After separation of 152Tb using cation exchange chromatography, it was
directly employed for radiolabeling of DOTANOC. PET/CT scans were performed with AR42J tumor-bearing mice
at different time points after injection of 152Tb-DOTANOC which was applied at variable molar peptide amounts.
177Lu-DOTANOC was prepared and used in biodistribution and SPECT/CT imaging studies for comparison with
the PET results.
Results: After purification, 152Tb was obtained at activities up to ~600 MBq. Radiolabeling of DOTANOC was achieved at
a specific activity of 10 MBq/nmol with a radiochemical purity >98 %. The PET/CT scans of mice allowed visualization of
AR42J tumor xenografts and the kidneys, in which the radiopeptide was accumulated. After injection of large peptide
amounts, the tumor uptake was reduced as compared to the result after injection of small peptide amounts. PET images
of mice, which received 152Tb-DOTANOC at small peptide amounts, revealed the best tumor-to-kidney ratios. The data
obtained with 177Lu-DOTANOC in biodistribution and SPECT/CT imaging studies confirmed the 152Tb-based PET results.
Conclusions: Production of 30-fold higher quantities of 152Tb as compared to the previously performed pilot study was
feasible. This allowed, for the first time, labeling of a peptide at a reasonable specific activity and subsequent application
for in vivo PET imaging. As a β+-particle-emitting radiolanthanide, 152Tb would be of distinct value for clinical application,
as it may allow exact prediction of the tissue distribution of therapeutic radiolanthanides.
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Background
Terbium has attracted the attention of researchers in ra-
diopharmaceutical sciences due to the existence of four
medically interesting radionuclides for SPECT (155Tb)
and PET (152Tb) imaging, as well as for α- (149Tb) and
β−-radionuclide (161Tb) therapy. The first proof-of-
concept study, using all four Tb radionuclides in com-
bination with a folate-based tumor targeting agent, has
been reported by Müller et al. [1]. It was demonstrated
that the production and preclinical application of these
four Tb nuclides is feasible. Of the four Tb nuclides,
161Tb is the most advanced with regard to the produc-
tion and separation methods, previously introduced by
Zhernosekov et al. [2] and currently implemented at PSI
[1]. In vivo studies have been performed in order to as-
sess the tissue distribution profile of 161Tb-labeled bio-
molecules and to investigate the therapeutic potential of
161Tb in comparison to the clinically- established 177Lu [3–
5]. Based on the results of these studies, it is likely that the
co-emitted Auger and conversion electrons of 161Tb con-
tributed positively to the overall anti-tumor effects, while
additional side effects to the kidneys were not observed [6].
Another interesting Tb nuclide for therapeutic purposes is
149Tb, which decays with a half-life of 4 h and the emission
of α-particles. Due to the currently limited availability of
this radionuclide, extended in vitro and in vivo studies have
not been performed yet. There is, however, a clear indi-
cation of its potential for α-radionuclide therapy, as
demonstrated in preclinical proof-of-concept studies with
149Tb-labeled rituximab [7] as well as with a 149Tb-labeled
DOTA-folate conjugate [8]. Just recently, we demon-
strated that 149Tb can also be used for PET imaging based
on the emission of β+-particles [9].
Two other Tb nuclides, 155Tb and 152Tb, are suited for
diagnostic applications. Recently, preclinical experiments
were performed in order to investigate 155Tb in more de-
tail with regard to its potential for SPECT imaging [10].
For this purpose, several DOTA-functionalized tumor
targeting agents, among those also peptides and an anti-
body, were employed for imaging of tumors in mice [10].
The image quality of the 155Tb-based SPECT scans was
convincing and allowed not only the visualization of sub-
cutaneous tumor xenografts, but also smallest lesions in
the abdominal tract of a mouse with intraperitoneal
SKOV-3ip xenografts [10]. 155Tb-based SPECT imaging
was also investigated using a Derenzo phantom, which
proved that the achievable image resolution was compar-
able to the resolution of 111In, a clinically well-established
SPECT nuclide [10].
Since PET is commonly the preferred imaging tech-
nique in nuclear medicine, the development of new PET
nuclides is of general interest. In this regard, 152Tb is a
promising candidate to be used for PET imaging based
on the emission of β+-particles, while co-emission of
therapeutic particles is absent (Table 1). The relatively
long half-life of 17.5 h appears particularly attractive, as
it may allow pre-therapeutic imaging, potentially useful
for dosimetry calculations prior to therapy with particle-
emitting radiolanthanides, such as 177Lu, 166Ho, 161Tb,
and 149Tb. The limited availability of 152Tb has, however,
prevented further in vivo imaging studies to date.
The aim of this study was to produce 152Tb at larger
quantities at the ISOL facility at CERN/ISOLDE and
process it to allow using it for in vivo studies. For this
purpose, DOTANOC, a clinically relevant peptide for tar-
geting the somatostatin receptor, was employed (Fig. 1)
[11–13].
Tumor-bearing mice were injected with the 152Tb-
labeled peptide in order to assess the potential of
152Tb for PET imaging using a preclinical PET/CT scan-
ner. The data obtained with 152Tb-DOTANOC were com-
pared with the tissue distribution data and SPECT image
obtained with the 177Lu-labeled counterpart in order to
corroborate the hypothesis that 152Tb could serve as a
surrogate for therapeutic radiolanthanides.
Methods
Production of 152Tb
152Tb was produced by 1.4 GeV proton-induced spalla-
tion in a tantalum foil target (55 g/cm2) at ISOLDE
(CERN, Geneva, Switzerland). The spallation products
were released online from the hot (~2000 °C) target and
ionized in a hot (~2000 °C) tungsten ionizer. The cumu-
lative 152Tb yields were significantly boosted by resonant
laser ionization [14] of the radioactive precursor 152Dy.
The ions were then accelerated to 30 keV and mass-
separated, as previously reported [1, 15]. Mass 152 ions
were implanted into zinc-coated gold foils.
Separation of 152Tb from target material and impurities
The zinc layer containing 152Tb, and other mass 152 im-
purities, was dissolved in 0.1 M HNO3/NH4NO3 at 80 °C.
After addition of H2O, the solution was passed through a
50 mm× 5 mm column containing a macroporous strongly
acidic cation exchange resin, as previously described
[1]. A concentration gradient of α-hydroxyisobutyric
acid (α-HIBA; pH 4.7) ranging from 0.07, 0.09, 0.11 to
0.13 M was used for elution. The gradient pump was
Table 1 Decay properties of 152Tb based on NuDat 2.6 (www.nndc.bnl.gov/nudat2/)
Nuclide Half-life Eβ+average (I) Significant γ-rays (I > 5 %); Eγ (I) Application
152Tb 17.5 h 1140 (20.3 %) 271 (9.53 %); 344 (63.5 %); 586 (9.21 %); 779 (5.54 %) PET imaging
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set to run at 0.33 mL/min, and ~1 mL fractions were
collected in pre-washed Eppendorf tubes. Fractions
containing the highest activity of 152Tb were used directly
in the subsequent radiolabeling of DOTANOC.
Radiolabeling of DOTANOC
DOTANOC was obtained from ABX GmbH (DOTA-
NOC acetate Cat-N° 9712). The peptide was dissolved in
MilliQ water to obtain a stock solution of 1 mM. The
radiolabeling with 152Tb was performed by direct addition
of 12 μL DOTANOC stock solution to a 152Tb-α-HIBA
solution (120 MBq in ~500 μL, pH 4.7). The reaction mix-
ture was incubated at 95 °C for 15 min. Labeling of
DOTANOC with n.c.a. 177Lu (Isotope Technologies
Garching ITG GmbH, Germany) was performed under
standard conditions in a mixture of HCl (0.05 M) and Na-
acetate (0.5 M) at pH 4.5 and elevated temperature
(15 min, 95 °C). High-performance liquid chromatography
(HPLC) with a C-18 reversed-phase column (Xterra™ MS,
C18, 5 μm, 150 × 4.6 mm; Waters) was used for quality
control of the radiolabeled peptides. The mobile phase
consisted of MilliQ water containing 0.1 % trifluoroacetic
acid (A) and acetonitrile (B). A gradient from 95 % A and
5 % B to 20 % A and 80 % B over a period of 15 min was
used with a flow rate of 1.0 mL/min. The product peak
corresponding to 152Tb-DOTANOC and 177Lu-DOTA-
NOC, respectively, appeared with a retention time (Rt) of
11.1 min.
Cell culture
AR42J tumor cells, a rat exocrine pancreatic tumor cell
line which is known to express the somatostatin recep-
tor, were obtained from the European Collection of Cell
Cultures (ECACC). The cells were cultured in RPMI
1640 medium, supplemented with 10 % fetal calf serum,
L-glutamine, and antibiotics under standard conditions
in a humidified atmosphere with 5 % CO2 at 37 °C.
Routine culture was performed by trypsinization of the
cells twice a week. To inoculate the animals, the cells were
detached using trypsin, centrifuged, and resuspended in
PBS at a concentration of 5 × 106 cells/100 μL.
Tumor mouse model
In vivo experiments were approved by the local veter-
inary department and conducted in accordance with
the Swiss law of animal protection. Female nude mice
(CD-1 Foxn-1/nu) were purchased from Charles River
Laboratories (Sulzfeld, Germany). The animals were
fed with a standard rodent chow ad libitum (Kliba Nafag,
Kaiseraugst, Switzerland).
About 2 weeks prior to biodistribution and imaging
studies, the mice were inoculated with AR42J tumor
cells by subcutaneous injection of the cell suspension
(5 × 106 cells/100 μL) on each shoulder.
Biodistribution study of 177Lu-DOTANOC in AR42J
tumor-bearing mice
Biodistribution studies were performed in triplicate in
AR42J tumor-bearing nude mice. 177Lu-DOTANOC
(5 MBq, 2.5 nmol per mouse) was administered intra-
venously (i.v.) into a tail vein. Mice were euthanized at
pre-determined time points between 30 min and 22 h
after injection of the radioconjugate. Two additional
groups of three mice each were injected with 5 MBq
177Lu-DOTANOC and a peptide amount of 0.5 and
5.0 nmol, respectively. Selected tissues and organs were
collected, weighed, and counted for radioactivity using
a γ-counter (Packard Canberra Cobra II, USA). The re-
sults were listed as a percentage of the injected activity
per gram of tissue mass (% IA/g), using counts of a de-
fined volume of the original injection solution mea-
sured at the same time.
SPECT/CT imaging studies
SPECT scans were performed after the injection of
177Lu-DOTANOC using a NanoSPECT/CT™ (Mediso
Medical Imaging Systems, Budapest, Hungary) and
Nucline Software (version 1.02, Bioscan Inc., Poway, USA).
For this purpose, the energy peaks of 177Lu were set to
Fig. 1 Chemical structure of DOTANOC which was radiolabeled with 152Tb for PET, along with the radiation properties of 152Tb as obtained from
the Karlsruhe Nuclide Chart (www.nucleonica.com)
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56.1 keV ± 10 %, 112.9 keV ± 10 %, and 208.4 keV ± 10 %.
The acquired data were reconstructed using HiSPECT soft-
ware (version 1.4.3049, Scivis GmbH, Göttingen, Germany).
Images were prepared using the VivoQuant post-processing
software (version 2.1, inviCRO Imaging Services and
Software, Boston, USA). Accumulation of 177Lu-DOTA-
NOC per volume of tumor and kidney tissue was deter-
mined using the “3D ROI” tool of the the VivoQuant
post-processing software, allowing calculation of the
tumor-to-kidney ratios. A Gauss post-reconstruction
filter was applied for the presentation of the SPECT
image, and the scale was adjusted to allow the best
visualization of tumors and kidneys in which radio-
activity accumulated.
PET/CT imaging studies
PET scans were performed with a bench-top preclin-
ical PET/CT scanner (G8, Sofie Biosciences, California,
USA and Perkin Elmer, Massachusetts, USA). The energy
window ranged from 150 to 650 keV and the spatial reso-
lution of reconstructed images was 1.4 mm full-width-at-
half-maximum in the center of the field of view [16].
The images were acquired as static whole-body scans
using G8 acquisition software (version 1.2.9.3) and
reconstructed with maximum-likelihood expectation
maximization (MLEM). The data were corrected for
random coincidences, decay and dead time. Images
were prepared using the VivoQuant post-processing
software (version 2.1, inviCRO Imaging Services and
Software, Boston, USA). Accumulation of 152Tb-
DOTANOC per volume of tumor and kidney tissue
was determined using the “3D ROI” tool of the
VivoQuant post-processing software, allowing calcu-
lation of the tumor-to-kidney ratios. A Gauss post-
reconstruction filter was applied for the presentation
of the PET, with the scale adjusted to allow the best
visualization of tumors and kidneys in which radio-
activity accumulated.
Results
Production of 152Tb
Samples of ~1.3 GBq 152Tb were collected after online
mass separation at the ISOLDE facility of CERN and im-
planted into Zn plated on gold foils. Collections were
performed for 4-h periods utilizing a 2 μA, 1.4 GeV
proton beam on the spallation target. After leaving the
collected samples to stand, to allow the short-lived
precursor, 152Dy, as well as 136Nd and 136Pr which are
present as oxide sidebands to decay, the samples were
transported to PSI. Radiochemical separation was per-
formed 18 h after end of collection, when ~650 MBq
152Tb remained.
Separation of 152Tb
The radiochemical separation, based on cation exchange
chromatography, saw the collection of 12 1-mL samples,
yielding a total of ~600 MBq (>90 %) 152Tb in <2.5 mL
0.13 M α-HIBA. The gradient elution of the column at
low pump speeds ensured the sole elution of 152Tb, leav-
ing the remaining contaminants, predominantly Ce, to
be eluted with more concentrated solutions. The 152Tb
eluent was radiochemically pure and used directly for
radiolabeling purposes.
Preparation of radiopeptides
Radiolabeling of DOTANOC with 152Tb was achieved at
a specific activity of 10 MBq/nmol and a radiochemical
purity of >98 % as determined by radio-HPLC (Fig. 2).
The chromatogram indicated the onset of radiolysis,
evidenced by a shoulder (Rt = 10–11 min) before the
product peak (Rt = 11.1 min). This peak area was not
taken into consideration for determination of the radio-
chemical purity. Preparation of 177Lu-DOTANOC at a
specific activity of 10 MBq/nmol was readily achieved
with a radiochemical purity of >98 %.
The reaction mixture of 152Tb-DOTANOC and 177Lu-
DOTANOC, respectively, was diluted with saline for in
vivo application. Na-DTPA (5–10 μL, 5 mM, pH 5) was
added for complexation of potential traces of unreacted
152Tb and 177Lu, respectively.
Biodistribution study of 177Lu-DOTANOC in AR42J
tumor-bearing mice
Biodistribution studies were performed in AR42J tumor-
bearing nude mice at 30 min, 2 h, 5 h, 16 h, and 22 h
after injection of 177Lu-DOTANOC (5 MBq/2.5 nmol) in
order to quantify the tissue distribution of radioactivity
(Table 3). Based on the data obtained in these experi-
ments, the radioconjugate was quickly cleared from the
blood and accumulated in the tumor tissue, where it
reached a maximum uptake of 9.02 ± 0.33 % IA/g already
30 min after injection. Over the first 5 h, the uptake in the
Fig. 2 HPLC chromatogram of 152Tb-DOTANOC (Rt = 11.1 min, >98 %
radiochemical purity) showing the absence of unreacted 152Tb(III)
(Rt = 2.3 min, <1 %). Formation of radiolysis products are shown as
a shoulder of the main peak (Rt = 10–11 min)
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tumor remained almost constant, but it decreased later to
5.48 ± 0.98 % IA/g at 16 h and 4.51 ± 0.37 % IA/g at 22 h
after injection. In the kidneys, the highest value of accu-
mulated radioactivity (13.0 ± 1.85 % IA/g) was determined
30 min after injection of 177Lu-DOTANOC. The radio-
activity was cleared from the kidneys over time, resulting
in 4.80 ± 0.19 % IA/g at 22 h after injection. As a conse-
quence, the tumor-to-kidney ratios were ~1 within the
time window of 2 to 22 h after injection of 177Lu-
DOTANOC applied at the mentioned molar peptide
amount.
Additional experiments were conducted to investigate
the influence of the injected peptide amount (0.5, 2.5,
and 5.0 nmol, respectively) on the tissue distribution of
the radiopeptide. For this purpose, mice were euthanized
and dissected 5 h after injection of 177Lu-DOTANOC. It
was found that the absolute tumor uptake was highest
(25.3 ± 4.14 % IA/g) in mice which received the lowest
quantity of injected peptide (0.5 nmol), over threefold
reduced (8.45 ± 1.04 % IA/g) in mice which received
2.5 nmol peptide and almost sevenfold reduced (3.82 ±
0.20 % IA/g) in mice injected with 5.0 nmol peptide.
Accumulation of radioactivity in the kidneys was in the
range of ~6.6 % IA/g to ~9.1 % IA/g, 5 h after injection
of 177Lu-DOTANOC, independent of the molar amount
of injected peptide. It was, thus, revealed that the
tumor-to-kidney ratios were more favorable with the
injection of small molar amounts of peptide than after
injection of large quantities. The same holds true for
tumor-to-blood and tumor-to-liver ratios (Fig. 3).
PET/CT and SPECT/CT imaging studies
In vivo PET/CT studies were performed with a pre-
clinical G8 benchtop PET/CT scanner, which allowed
acquisition of high-quality PET/CT images at low ac-
tivities. Imaging studies were performed with AR42J
tumor-bearing mice at variable time points after injec-
tion of different quantities of activity and molar
amounts of 152Tb-DOTANOC (Table 2). In order to
investigate the tissue distribution at an early time
point, 3.4 MBq 152Tb-DOTANOC were injected, cor-
responding to 0.34 nmol DOTANOC. The mouse (M1,
Table 2) was scanned 2 h after injection of 152Tb-
DOTANOC. At this time, the activity in the animal
was only ~0.52 MBq, which is an optimum quantity to
perform PET scans with the highly sensitive G8 scan-
ner. The in vivo PET scan of the mouse lasted for
20 min and was followed by a CT scan of 1.5 min. The
resulting PET/CT image showed high uptake of radio-
activity in AR42J tumor xenografts and, as a consequence
of the excretion of 152Tb-DOTANOC, retention of activity
was also found in the kidneys as well as in the urinary
bladder (Fig. 4). The tumor-to-kidney ratio determined
using VivoQuant software revealed a value of ~1.5. The
increased tumor-to-kidney ratio after injection of low
molar amounts of DOTANOC was in agreement with the
results of the biodistribution study using 177Lu-DOTA-
NOC, where the tumor-to-kidney ratio was found to
be ~3.8 at 5 h after injection of low molar peptide
amounts (0.5 nmol) (Fig. 3, Additional file 1: Table S1).
In a subsequent experiment, the tissue distribution
was investigated at later time points after injection.
Another mouse (M2, Table 2) was, therefore, injected
with a larger quantity of 152Tb-DOTANOC (25 MBq),
which corresponded to a molar amount of 2.5 nmol pep-
tide. The same molar amount was also used in biodistri-
bution studies with 177Lu-DOTANOC (Table 3). The in
vivo PET scans, which were performed at 5, 8, and 22 h
after injection, lasted for 20 min and were followed by a
CT scan of 1.5 min. At these time points, the activity in the
mouse was reduced to ~1.87, ~1.46, and ~0.44 MBq, re-
spectively. The PET/CT images of the mouse showed
significant accumulation of radioactivity in AR42J tumor
xenografts located on each shoulder, as well as in the kid-
neys (Fig. 5a–c). Determination of the tumor-to-kidney
ratios using VivoQuant software revealed values in the
range of ~1 at all investigated time points (~1.1 at 5 h
p.i., ~1.1 at 8 h p.i., and ~1.2 at 22 h p.i.). The findings
were in good agreement with the values (~0.94) ob-
tained in biodistribution studies performed in the same
Fig. 3 Tumor-to-background ratios of 177Lu-DOTANOC obtained after injection of three different molar amounts of injected peptide (0.5, 2.5, and
5.0 nmol). a Tumor-to-blood ratios, b tumor-to-liver ratios, and c tumor-to-kidney ratios
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tumor mouse model after injection of the same molar
amount of 177Lu-DOTANOC (Table 3).
A third mouse (M3, Table 2) was injected with even
larger quantities of 152Tb-DOTANOC (47 MBq, 4.7 nmol
DOTANOC) which would be ideal to perform scans at
later time points after injection. The PET/CT scan was
performed 22 h after injection of 152Tb-DOTANOC,
when ~0.83 MBq were left in the animal. The PET scan
lasted for 20 min and was followed by a CT scan of
1.5 min. To directly compare this with the tissue distri-
bution of 177Lu-DOTANOC, a SPECT/CT scan was per-
formed with a mouse which received 177Lu-DOTANOC
at the same molar amount of peptide. At scan start, 22 h
after injection, only ~2.5 MBq 177Lu were counted in
this mouse. As this activity was too low for a short
SPECT scan, the mouse was scanned for 4 h post-
mortem in order to allow acquisition of sufficient
counts. The CT, which was performed before the start of
the SPECT scan, lasted for 7.5 min. The PET/CT and
SPECT/CT images showed equal tissue distribution pro-
files of the two radioconjugates (Fig. 6a, b). Determin-
ation of the tumor-to-kidney ratios using the VivoQuant
software revealed a value of ~1.0 for 177Lu-DOTANOC
and ~1.1 was determined for 152Tb-DOTANOC. In bio-
distribution studies performed with 177Lu-DOTANOC,
the relatively high molar amount of 5 nmol injected pep-
tide resulted in a decreased tumor-to-kidney ratio
(~0.55) at 5 h after injection of 177Lu-DOTANOC (Fig. 3,
Additional file 1: Table S1). This indicates that, over
time, the radioactivity was cleared faster from the kid-
neys than from tumors, resulting in increasing tumor-
to-kidney ratios of ~1 at later time points after injection.
Discussion
There are only few instances in preclinical studies where
152Tb has been used [1, 17]. The present study is the first
in which 152Tb (available at ~30-fold higher quantities)
could be employed for detailed in vivo PET imaging using
tumor-bearing mice and a well-established somatostatin
receptor targeting peptide. A unique and indisputable
advantage of 152Tb, as compared to currently used 68Ga, is
the possibility to use it for imaging purposes over a longer
period. It may find application as a diagnostic and dosim-
etry match for clinically-used therapeutic radionuclides,
such as 177Lu and 166Ho, or for the exact therapeutic
matches 161Tb and 149Tb. In this regard, it may be of
particular value in combination with targeting agents of a
longer biological half-life such as albumin-binding small
molecules or antibodies. Although other longer-lived PET
nuclides such as 89Zr (T1/2 = 3.26 days) and
64Cu (T1/2 =
12.7 h) exist, these nuclides have different chemical prop-
erties and, hence, different chelators are necessary for
stable coordination [18–20]. 68Ga is currently successfully
used for PET imaging prior to 177Lu-based radionuclide
therapy [11, 21], however, its short half-life and different
coordination chemistry, which may result in different
pharmacokinetics [22], would clearly speak in the favor of
using a matched radiolanthanide for PET and, thus, justify
the development and investigation of 152Tb.
In the proof-of-concept study in which 152Tb was used
for the first time in vivo, only 20 MBq of 152Tb were
available after separation, allowing labeling of a DOTA-
folate conjugate at a low specific activity of 1.3 MBq/
nmol [1]. As a consequence, relatively high molar
amounts of the folate conjugate (~7 nmol) had to be
injected in order to only obtain PET images at short
time points (1.5 and 3 h) after injection, while imaging
the following day was only possible post-mortem due to
the long acquisition time which was required [1]. In the
present study, a ~30-fold increased activity was obtained
allowing radiolabeling at a markedly higher specific ac-
tivity of 10 MBq/nmol. Such improvement was feasible
due to significantly higher activities which were pro-
duced, allowing the performance of the radiolabeling
with higher activity concentrations.
Partial degradation of the peptide, as a consequence of
radiolysis, was observed as a shoulder of the product
peak—a phenomenon which is more pronounced with
Table 2 Experimental design of the PET/CT and SPECT/CT imaging studies
Mouse Radiopeptide Injected activity (IA) Injected DOTANOC Scan start
(scan duration)
Radioactivity at
scan start
Imaging method Figure
M1 152Tb-DOTANOC ~3.4 MBq 0.34 nmol 2 h p.i. (20 min) ~0.52 MBq PET/CT Fig. 4
M2 152Tb-DOTANOC ~25 MBq 2.5 nmol 5 h p.i. (20 min) ~1.87 MBq PET/CT Fig. 5a
8 h p.i. (20 min) ~1.46 MBq PET/CT Fig. 5b
22 h p.i. (20 min) ~0.44 MBq PET/CT Fig. 5c
M3 152Tb-DOTANOC ~47 MBq 4.7 nmol 22 h p.i. (30 min) ~0.83 MBq PET/CT Fig. 6a
32 h p.i. (30 min) ~0.45 MBq PET/CT Additional file 1:
Fig. S1a
M4 177Lu-DOTANOC ~47 MBq 4.7 nmol 22 h p.i. (4 h)b ~2.5 MBq SPECT/CT Fig. 6b
a
bPost-mortem scan
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increasing radioactivity concentrations. The addition of
ascorbic acid or gentisic acid to the labeling solution
would, most likely, prevent this process completely, as
previously demonstrated by our group when using 44Sc
(Eβ+av = 632 keV, Iβ+ = 94 %, Eγ = 1157 keV, Iγ = 99.9 %;
T1/2 = 3.97 h) for labeling of the same peptide [23]. It
will be of interest to investigate the extent of radiolysis
with 152Tb-labeled peptides in more detail in future ex-
periments. In addition, comparison with peptides, la-
beled with conventional PET nuclides like 68Ga, would
be interesting and allow the development of suitable la-
beling and storage conditions under the application of
commonly used scavengers.
The high sensitivity G8 PET/CT scanner allowed the
performance of PET scans with low activities within a
short acquisition time. It was, therefore, possible for the
first time to perform in vivo PET/CT scans up to 22 h
after administration of the 152Tb-labeled compound.
The mouse which received 47 MBq 152Tb-DOTANOC
was also successfully scanned at 32 h after injection as
the longest time point of investigation (Additional file 1:
Fig. S1).
The PET/CT experiments performed in this study cor-
roborated the hypothesis that 152Tb can be used as a
diagnostic match to 177Lu, as the images reflected what
was expected based on biodistribution experiments
using 177Lu-DOTANOC. It was also demonstrated that
the molar amount of injected peptide was crucial with
regard to the tumor uptake of radioactivity and, as a re-
sult, the tumor-to-kidney ratios. These findings are in
agreement with previous findings reported in the litera-
ture, which showed that therapeutic quantities of injected
peptide may saturate the receptors in somatostatin
receptor-positive tissue [24]. In the present study, low
peptide amounts (0.5 nmol) showed a clearly higher
tumor uptake (~25 % IA/g, 5 h p.i.) as compared to 10-
fold higher peptide amounts which resulted in a markedly
reduced accumulation in the tumor (~4 % IA/g, 5 h p.i.).
These findings were also reflected by the fact that excre-
tion of radioactivity injected into mice was slower if small
amounts of peptide were used because, in this case, a lar-
ger fraction was accumulated and retained in the tumor
tissue (Additional file 1: Fig. S2). Such results are, however,
dependent on the tumor type, the tumor size, and its
receptor expression level. It may be different for other tar-
geting agents and, hence, such effects have to be carefully
Fig. 4 PET/CT image shown as maximal intensity projection of an
AR42J tumor-bearing mouse 2 h after injection of Tb-DOTANOC (3.4
MBq; 0.34 nmol DOTANOC). During the in vivo scan the mouse was
anesthetized with a mixture of isoflurane and oxygen. The image is
presented with the scale adapted to allow visualization of tumors and
kidneys. (Tu = AR42J tumor xenograft, Ki = kidney, Bl = urinary bladder)
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Table 3 Biodistribution of 177Lu-DOTANOC (5 MBq/2.5 nmol) in AR42J tumor-bearing female nude mice, expressed in percentage of
total injected activity per gram tissue (% IA/g)
177Lu-DOTANOC
30 min p.i. 2 h p.i. 5 h p.i. 16 h p.i. 22 h p.i.
Blood 2.52 ± 0.65 0.09 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 0.03 ± 0.00
Heart 1.34 ± 0.35 0.08 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.03 ± 0.00
Lung 3.04 ± 0.47 0.45 ± 0.03 0.41 ± 0.04 0.27 ± 0.05 0.21 ± 0.03
Spleen 0.77 ± 0.03 0.15 ± 0.01 0.18 ± 0.02 0.13 ± 0.04 0.09 ± 0.01
Kidneys 13.0 ± 1.85 7.67 ± 0.51 9.10 ± 1.66 6.13 ± 1.63 4.80 ± 0.19
Adrenals 1.38 ± 0.32 0.28 ± 0.14 0.37 ± 0.05 0.51 ± 0.40 0.42 ± 0.18
Stomach 1.95 ± 0.23 1.14 ± 0.04 1.21 ± 0.55 0.68 ± 0.09 0.60 ± 0.22
Pancreas 1.99 ± 0.07 1.09 ± 0.17 0.88 ± 0.11 0.34 ± 0.05 0.25 ± 0.03
Intestines 0.94 ± 0.12 0.25 ± 0.04 0.25 ± 0.03 0.16 ± 0.01 0.13 ± 0.03
Liver 1.43 ± 0.17 0.52 ± 0.04 0.53 ± 0.10 0.27 ± 0.05 0.20 ± 0.02
Muscle 0.48 ± 0.16 0.02 ± 0.00 0.02 ± 0.01 0.03 ± 0.00 0.01 ± 0.00
Bone 1.13 ± 0.26 0.17 ± 0.01 0.12 ± 0.02 0.12 ± 0.05 0.08 ± 0.01
Brain 0.06 ± 0.01 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.01 0.01 ± 0.00
AR42J tumor 9.02 ± 0.33 8.32 ± 0.47 8.45 ± 1.04 5.48 ± 0.98 4.51 ± 0.37
Tumor-to-blood 3.76 ± 1.05 96.6 ± 8.79 137 ± 15.3 80.0 ± 8.30 180 ± 17.5
Tumor-to-liver 6.39 ± 0.89 16.1 ± 1.34 16.2 ± 2.10 21.0 ± 2.68 23.0 ± 2.96
Tumor-to-kidney 0.71 ± 0.11 1.09 ± 0.06 0.94 ± 0.16 0.93 ± 0.19 0.94 ± 0.02
Values shown represent the mean ± S.D. of data from three animals (n = 3) per cohort
Fig. 5 a–c PET/CT images shown as maximal intensity projections of an AR42J tumor-bearing mouse at different time points after injection of
152Tb-DOTANOC (25 MBq; 2.5 nmol DOTANOC). a PET/CT image at 5 h after injection of 152Tb-DOTANOC; b PET/CT image at 8 h after injection of
152Tb-DOTANOC, and c PET/CT image at 22 h after injection of 152Tb-DOTANOC. During the in vivo scan, the mouse was anesthetized with a
mixture of isoflurane and oxygen. The images are presented with the scale kept at an equal level for all time points in order to reflect the
effective activity retained in the mouse. (Tu AR42J tumor xenograft, Ki kidney)
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evaluated for each single targeting concept and tumor
mouse model. In the case of using DOTANOC in AR42J
tumor-bearing mice, our results clearly demonstrated how
crucial it would be to inject the same peptide amount for
diagnosis and therapy in order to allow visualization of the
effective tissue distribution expected for the therapeutic
match.
While the limited availability of 152Tb was considered
as a hindrance for further investigations to date, new
endeavors are focused on overcoming this obstacle. The
present study demonstrated an increase in obtained
radioactivity by a factor 30 with respect to our previ-
ously published pilot study [1]. In the near future, it is
foreseen to increase the 152Tb activities further by using
thicker tantalum targets that may result in a gain of a
factor 2-4, as well as longer collection times resulting in
an additional gain of activity of up to a factor 6.
MEDICIS, a new radionuclide production center dedi-
cated to medical applications, is being built at CERN
(Geneva, Switzerland). Other facilities exploiting spallation
production combined with isotope separation online are
under operation at ISAC, TRIUMF (Vancouver, Canada)
and IRIS, PNPI (Gatchina, Russia). New facilities are
planned or under construction at RIBF (East Lansing,
USA), ISOL@MYRRHA (Mol, Belgium), and J-PARC
ISOL (Tokai, Japan). Such facilities will provide about
two orders of magnitude higher proton current on
target compared to the proton current used for the
present study, thus, the production of 152Tb by spalla-
tion and coupled to mass separation has the potential
to produce in the range of TBq per day. Such activity
would correspond to several hundreds of patient doses.
Alternative production at compact cyclotrons via the
152Gd (p,n)152Tb reaction with 12 MeV protons, followed
by radiochemical Gd/Tb separation [25] is feasible once
highly enriched 152Gd becomes commercially available.
One can assume that the more regular production of
152Tb will be possible in the near future and provide quan-
tities sufficient for pilot investigations in patients.
Conclusions
In this study, 152Tb was produced at significantly higher
quantities (30 times more) than previously achieved.
These circumstances allowed the performance of more
detailed imaging studies with tumor-bearing mice using
in vivo PET/CT. Based on the resulting data, 152Tb is a
promising candidate to be used as diagnostic match to
therapeutic radiolanthanides, potentially allowing exact
pre-therapeutic imaging and dosimetry calculations.
More regular production of 152Tb at high quantities will
be crucial to allow further preclinical investigations, as
well as pilot studies in the clinics.
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